Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18199495 | 0.95 | SMN1; SMN2 (0.66) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL9976345 | 0.91 | KMT2A (0.64) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL17472230 | 0.91 | SMN1; SMN2 (0.58) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL19757992 | 0.91 | SMN1; SMN2 (0.58) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL18908668 | 0.90 | SMN1; SMN2 (0.59) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL24118140 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL7325345 | 0.89 | SMN1; SMN2 (0.59) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL10088093 | 0.89 | SMN1; SMN2 (0.59) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL4845341 | 0.89 | SMN1; SMN2 (0.59) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL20341082 | 0.88 | CASP2 (0.60) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-06-27 | — | — | US | disclosed |
| US-20220000981-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2022-01-06 | — | — | US | disclosed |
| US-11007252-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-05-18 | — | — | US | disclosed |
| US-10039809-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-08-07 | — | — | US | disclosed |
| US-10039809-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-08-07 | — | — | US | disclosed |
| US-10010589-B2 | — | — | 2018-07-03 | — | — | US | disclosed |
| US-10010589-B2 | — | — | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000981-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | SMN1; SMN2 1134/4885TP53 581/4885ALDH1A1 4240/4885 |
| US-11007252-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | SGMS1, SGMS2, PHOSPHO1 | SMN1; SMN2 1134/4885TP53 581/4885ALDH1A1 4240/4885 |
| US-10010589-B2 | — | TYMP, MTAP, TUBB6 | SMN1; SMN2 599/4885TP53 325/4885ALDH1A1 3205/4885 |
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | SMN1; SMN2 1134/4885TP53 581/4885ALDH1A1 4240/4885 |
| US-10039809-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | SGMS1, SGMS2, PHOSPHO1 | SMN1; SMN2 1134/4885TP53 581/4885ALDH1A1 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.